Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.

McCarten KM, Nadel HR, Shulkin BL, Cho SY.

Pediatr Radiol. 2019 Oct;49(11):1545-1564. doi: 10.1007/s00247-019-04529-8. Epub 2019 Oct 16. Review.

PMID:
31620854
2.

A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma.

Furman WL, Federico SM, McCarville MB, Shulkin BL, Davidoff AM, Krasin MJ, Sahr N, Sykes A, Wu J, Brennan RC, Bishop MW, Helmig S, Stewart E, Navid F, Triplett B, Santana VM, Bahrami A, Anthony G, Yu AL, Hank J, Gillies SD, Sondel PM, Leung WH, Pappo AS.

Clin Cancer Res. 2019 Oct 10. doi: 10.1158/1078-0432.CCR-19-1452. [Epub ahead of print]

PMID:
31601569
3.

Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study.

Shusterman S, Naranjo A, Van Ryn C, Hank JA, Parisi MT, Shulkin BL, Servaes S, London WB, Shimada H, Gan J, Gillies SD, Maris JM, Park JR, Sondel PM.

Clin Cancer Res. 2019 Oct 15;25(20):6044-6051. doi: 10.1158/1078-0432.CCR-19-0798. Epub 2019 Jul 29.

PMID:
31358541
4.

68Ga-DOTATOC PET/CT in the localization of head and neck paraganglioma compared with 18F-DOPA PET/CT and 123I-MIBG SPECT/CT.

Kroiss AS, Uprimny C, Shulkin BL, Gruber L, Frech A, Url C, Riechelmann H, Sprinzl GM, Thomé C, Treglia G, Kjaer A, Fraedrich G, Virgolini IJ.

Nucl Med Biol. 2019 Apr;71:47-53. doi: 10.1016/j.nucmedbio.2019.04.003. Epub 2019 Apr 29.

PMID:
31152973
5.

Positron Emission Tomography Detects In Vivo Expression of Disialoganglioside GD2 in Mouse Models of Primary and Metastatic Osteosarcoma.

Butch ER, Mead PE, Amador Diaz V, Tillman H, Stewart E, Mishra JK, Kim J, Bahrami A, Dearling JLJ, Packard AB, Stoddard SV, Vāvere AL, Han Y, Shulkin BL, Snyder SE.

Cancer Res. 2019 Jun 15;79(12):3112-3124. doi: 10.1158/0008-5472.CAN-18-3340. Epub 2019 Apr 23.

PMID:
31015228
6.

Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy.

Tinkle CL, Williams NL, Wu H, Wu J, Kaste SC, Shulkin BL, Talleur AC, Flerlage JE, Hudson MM, Metzger ML, Krasin MJ.

Radiother Oncol. 2019 May;134:89-95. doi: 10.1016/j.radonc.2019.01.026. Epub 2019 Feb 5.

PMID:
31005229
7.

Multi-level otsu method to define metabolic tumor volume in positron emission tomography.

Im HJ, Solaiyappan M, Lee I, Bradshaw T, Daw NC, Navid F, Shulkin BL, Cho SY.

Am J Nucl Med Mol Imaging. 2018 Dec 20;8(6):373-386. eCollection 2018.

8.

68Ga-DOTATOC PET/CT in the localization of metastatic extra-adrenal paraganglioma and pheochromocytoma compared with 18F-DOPA PET/CT.

Kroiss AS, Uprimny C, Shulkin BL, Gruber L, Frech A, Jazbec T, Girod PP, Url C, Thomé C, Riechelmann H, Sprinzl GM, Fraedrich G, Virgolini IJ.

Rev Esp Med Nucl Imagen Mol. 2019 Mar - Apr;38(2):94-99. doi: 10.1016/j.remn.2018.09.004. Epub 2019 Jan 7. English, Spanish.

PMID:
30630744
9.

Efficacy of radioactive iodine treatment of graves' hyperthyroidism using a single calculated 131I dose.

Wong KK, Shulkin BL, Gross MD, Avram AM.

Clin Diabetes Endocrinol. 2018 Nov 28;4:20. doi: 10.1186/s40842-018-0071-6. eCollection 2018.

10.

Pediatric Musculoskeletal Imaging: The Indications for and Applications of PET/Computed Tomography.

Khalatbari H, Parisi MT, Kwatra N, Harrison DJ, Shulkin BL.

PET Clin. 2019 Jan;14(1):145-174. doi: 10.1016/j.cpet.2018.08.008. Epub 2018 Oct 24. Review.

PMID:
30420216
11.

The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.

Malempati S, Weigel BJ, Chi YY, Tian J, Anderson JR, Parham DM, Teot LA, Rodeberg DA, Yock TI, Shulkin BL, Spunt SL, Meyer WH, Hawkins DS.

Cancer. 2019 Jan 15;125(2):290-297. doi: 10.1002/cncr.31770. Epub 2018 Oct 23.

PMID:
30351457
12.

Managing local-regional failure in children with high-risk neuroblastoma: A single institution experience.

Dove AP, Manole BA, Wakefield DV, Cross SJ, Doubrovin M, Shulkin BL, Merchant TE, Davidoff AM, Furman WL, Krasin MJ, Santana VM, Lucas JT Jr.

Pediatr Blood Cancer. 2018 Dec;65(12):e27408. doi: 10.1002/pbc.27408. Epub 2018 Sep 30.

PMID:
30270551
13.

Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma.

Sokol EA, Engelmann R, Kang W, Pinto N, Starkey A, Lai H, Nadel H, Shulkin BL, Pu Y, Appelbaum D, Yanik GA, Cohn SL, Armato SG 3rd, Volchenboum S.

Pediatr Blood Cancer. 2018 Dec;65(12):e27417. doi: 10.1002/pbc.27417. Epub 2018 Sep 10.

PMID:
30198643
14.

The role of routine imaging in pediatric cutaneous melanoma.

Halalsheh H, Kaste SC, Navid F, Bahrami A, Shulkin BL, Rao B, Kunkel M, Artz N, Pappo A.

Pediatr Blood Cancer. 2018 Dec;65(12):e27412. doi: 10.1002/pbc.27412. Epub 2018 Aug 19.

PMID:
30124237
15.

Evaluation of 11C-Methionine PET and Anatomic MRI Associations in Diffuse Intrinsic Pontine Glioma.

Tinkle CL, Duncan EC, Doubrovin M, Han Y, Li Y, Kim H, Broniscer A, Snyder SE, Merchant TE, Shulkin BL.

J Nucl Med. 2019 Mar;60(3):312-319. doi: 10.2967/jnumed.118.212514. Epub 2018 Aug 2.

16.

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL.

Front Immunol. 2018 Jul 16;9:1641. doi: 10.3389/fimmu.2018.01641. eCollection 2018.

17.

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL.

Front Immunol. 2018 Jun 18;9:1355. doi: 10.3389/fimmu.2018.01355. eCollection 2018. Erratum in: Front Immunol. 2018 Jul 16;9:1641.

18.

FDG-PET CT in the evaluation of primary and secondary pancreatic malignancies.

Bohl CE, Federico SM, Robinson GW, Bahrami A, Shulkin BL.

Pediatr Blood Cancer. 2018 Oct;65(10):e27115. doi: 10.1002/pbc.27115. Epub 2018 May 11.

PMID:
29750397
19.

Radiomics Features Differentiate Between Normal and Tumoral High-Fdg Uptake.

Hsu CY, Doubrovin M, Hua CH, Mohammed O, Shulkin BL, Kaste S, Federico S, Metzger M, Krasin M, Tinkle C, Merchant TE, Lucas JT Jr.

Sci Rep. 2018 Mar 2;8(1):3913. doi: 10.1038/s41598-018-22319-4.

20.

Radionuclide Imaging of Infection and Inflammation in Children: a Review.

Parisi MT, Otjen JP, Stanescu AL, Shulkin BL.

Semin Nucl Med. 2018 Mar;48(2):148-165. doi: 10.1053/j.semnuclmed.2017.11.002. Epub 2017 Nov 28. Review.

PMID:
29452618
21.

Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study.

Im HJ, Zhang Y, Wu H, Wu J, Daw NC, Navid F, Shulkin BL, Cho SY.

Radiology. 2018 Apr;287(1):303-312. doi: 10.1148/radiol.2017162758. Epub 2018 Jan 19.

PMID:
29357275
22.

Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.

Ladenstein R, Lambert B, Pötschger U, Castellani MR, Lewington V, Bar-Sever Z, Oudoux A, Śliwińska A, Taborska K, Biassoni L, Yanik GA, Naranjo A, Parisi MT, Shulkin BL, Nadel H, Gelfand MJ, Matthay KK, Park JR, Kreissman SG, Valteau-Couanet D, Boubaker A.

Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):292-305. doi: 10.1007/s00259-017-3829-7. Epub 2017 Sep 23.

23.

A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.

Federico SM, McCarville MB, Shulkin BL, Sondel PM, Hank JA, Hutson P, Meagher M, Shafer A, Ng CY, Leung W, Janssen WE, Wu J, Mao S, Brennan RC, Santana VM, Pappo AS, Furman WL.

Clin Cancer Res. 2017 Nov 1;23(21):6441-6449. doi: 10.1158/1078-0432.CCR-17-0379. Epub 2017 Sep 22.

24.

CT-based SPECT attenuation correction and assessment of infarct size: results from a cardiac phantom study.

Kroiss AS, Nekolla SG, Dobrozemsky G, Grubinger T, Shulkin BL, Schwaiger M.

Ann Nucl Med. 2017 Dec;31(10):764-772. doi: 10.1007/s12149-017-1211-2. Epub 2017 Sep 21.

PMID:
28936780
25.

FDG PET/CT appearance of local osteosarcoma recurrences in pediatric patients.

Sharp SE, Shulkin BL, Gelfand MJ, McCarville MB.

Pediatr Radiol. 2017 Dec;47(13):1800-1808. doi: 10.1007/s00247-017-3963-1. Epub 2017 Sep 8.

PMID:
28887617
26.

Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.

Yanik GA, Parisi MT, Naranjo A, Nadel H, Gelfand MJ, Park JR, Ladenstein RL, Poetschger U, Boubaker A, Valteau-Couanet D, Lambert B, Castellani MR, Bar-Sever Z, Oudoux A, Kaminska A, Kreissman SG, Shulkin BL, Matthay KK.

J Nucl Med. 2018 Mar;59(3):502-508. doi: 10.2967/jnumed.117.195883. Epub 2017 Sep 8.

27.

Nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) in pediatric and young adult patients: Results from a prospective study using limited-margin radiotherapy.

Tinkle CL, Fernandez-Pineda I, Sykes A, Lu Z, Hua CH, Neel MD, Bahrami A, Shulkin BL, Kaste SC, Pappo A, Spunt SL, Krasin MJ.

Cancer. 2017 Nov 15;123(22):4419-4429. doi: 10.1002/cncr.30793. Epub 2017 Jul 31.

28.

A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy.

Navid F, Santana VM, Neel M, McCarville MB, Shulkin BL, Wu J, Billups CA, Mao S, Daryani VM, Stewart CF, Kunkel M, Smith W, Ward D, Pappo AS, Bahrami A, Loeb DM, Reikes Willert J, Rao BN, Daw NC.

Int J Cancer. 2017 Oct 1;141(7):1469-1477. doi: 10.1002/ijc.30841. Epub 2017 Jul 3.

29.

18F-FDG Uptake During Early Adjuvant Chemotherapy Predicts Histologic Response in Pediatric and Young Adult Patients with Osteosarcoma.

Davis JC, Daw NC, Navid F, Billups CA, Wu J, Bahrami A, Jenkins JJ, Snyder SE, Reddick WE, Santana VM, McCarville MB, Guo J, Shulkin BL.

J Nucl Med. 2018 Jan;59(1):25-30. doi: 10.2967/jnumed.117.190595. Epub 2017 Jun 13.

30.

Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.

Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R.

Lancet Oncol. 2017 Jul;18(7):946-957. doi: 10.1016/S1470-2045(17)30355-8. Epub 2017 May 23.

31.

Targeting Metabolic Reprogramming by Influenza Infection for Therapeutic Intervention.

Smallwood HS, Duan S, Morfouace M, Rezinciuc S, Shulkin BL, Shelat A, Zink EE, Milasta S, Bajracharya R, Oluwaseum AJ, Roussel MF, Green DR, Pasa-Tolic L, Thomas PG.

Cell Rep. 2017 May 23;19(8):1640-1653. doi: 10.1016/j.celrep.2017.04.039.

32.

Reply: The Need for Prudence When Using 18F-FDG PET as a Reference Standard for Lymphoma Detection.

Kaste SC, Metzger M, Shulkin BL.

J Nucl Med. 2017 Aug;58(8):1355. doi: 10.2967/jnumed.117.190652. Epub 2017 Apr 27. No abstract available.

33.

Optimization of Pediatric PET/CT.

Parisi MT, Bermo MS, Alessio AM, Sharp SE, Gelfand MJ, Shulkin BL.

Semin Nucl Med. 2017 May;47(3):258-274. doi: 10.1053/j.semnuclmed.2017.01.002. Epub 2017 Feb 16. Review.

PMID:
28417855
34.

The Role of 18F-FDG-PET/CT in Pediatric Sarcoma.

Harrison DJ, Parisi MT, Shulkin BL.

Semin Nucl Med. 2017 May;47(3):229-241. doi: 10.1053/j.semnuclmed.2016.12.004. Epub 2017 Jan 18. Review.

PMID:
28417853
35.

MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

DuBois SG, Mody R, Naranjo A, Van Ryn C, Russ D, Oldridge D, Kreissman S, Baker DL, Parisi M, Shulkin BL, Bai H, Diskin SJ, Batra V, Maris JM, Park JR, Matthay KK, Yanik G.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26545. Epub 2017 Apr 6.

36.

Compared to 123I-MIBG SPECT/CT, 18F-DOPA PET/CT provides accurate tumor extent in patients with extra-adrenal paraganglioma.

Kroiss AS, Uprimny C, Shulkin BL, Frech A, Tilg H, Gasser RW, Sprinzl GM, Gruber L, Thomé C, Plangger C, Url C, Fraedrich G, Virgolini IJ.

Ann Nucl Med. 2017 Jun;31(5):357-365. doi: 10.1007/s12149-017-1162-7. Epub 2017 Mar 27.

PMID:
28349331
37.

11C-Methionine positron emission tomography delineates non-contrast enhancing tumor regions at high risk for recurrence in pediatric high-grade glioma.

Lucas JT Jr, Serrano N, Kim H, Li X, Snyder SE, Hwang S, Li Y, Hua CH, Broniscer A, Merchant TE, Shulkin BL.

J Neurooncol. 2017 Mar;132(1):163-170. doi: 10.1007/s11060-016-2354-z. Epub 2017 Jan 11.

PMID:
28078638
38.

Assessment of Chemotherapy Response in Ewing Sarcoma.

McCarville MB, Federico SM, Bishop MW, Pappo AS, Shulkin BL.

Radiology. 2016 Nov;281(2):647-649. No abstract available.

PMID:
27755931
39.

Comparison of 11C-Methionine and 18F-FDG PET/CT for Staging and Follow-up of Pediatric Lymphoma.

Kaste SC, Snyder SE, Metzger ML, Sandlund JT, Howard SC, Krasin M, Shulkin BL.

J Nucl Med. 2017 Mar;58(3):419-424. doi: 10.2967/jnumed.116.178640. Epub 2016 Sep 8.

40.

Comparison of (18) F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma.

Hurley C, McCarville MB, Shulkin BL, Mao S, Wu J, Navid F, Daw NC, Pappo AS, Bishop MW.

Pediatr Blood Cancer. 2016 Aug;63(8):1381-6. doi: 10.1002/pbc.26014. Epub 2016 Apr 15.

41.

¹³¹I-Metaiodobenzylguanidine Theranostics in Neuroblastoma: Historical Perspectives; Practical Applications.

Parisi MT, Eslamy H, Park JR, Shulkin BL, Yanik GA.

Semin Nucl Med. 2016 May;46(3):184-202. doi: 10.1053/j.semnuclmed.2016.02.002. Review.

PMID:
27067500
42.

Erratum to: Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.

Temple W, Mendelsohn L, Kim GE, Nekritz E, Gustafson WC, Lin L, Giacomini K, Naranjo A, Van Ryn C, Parisi MT, Shulkin BL, Yanik GA, Kreissman SG, Hogarty M, Matthay KK, DuBois SG.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1396. No abstract available.

PMID:
27044383
43.

Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma.

Navid F, Herzog CE, Sandoval J, Daryani VM, Stewart CF, Gattuso J, Mandrell B, Phipps S, Chemaitilly W, Sykes A, Davidoff AM, Shulkin BL, Bahrami A, Furman WL, Mao S, Wu J, Schiff D, Rao B, Pappo A.

Pediatr Blood Cancer. 2016 Jul;63(7):1207-13. doi: 10.1002/pbc.25983. Epub 2016 Apr 1.

44.

Efficient automated syntheses of high specific activity 6-[18F]fluorodopamine using a diaryliodonium salt precursor.

Neumann KD, Qin L, Vāvere AL, Shen B, Miao Z, Chin FT, Shulkin BL, Snyder SE, DiMagno SG.

J Labelled Comp Radiopharm. 2016 Jan;59(1):30-4. doi: 10.1002/jlcr.3367. Epub 2015 Dec 23.

45.

Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI.

Guo J, Glass JO, McCarville MB, Shulkin BL, Daryani VM, Stewart CF, Wu J, Mao S, Dwek JR, Fayad LM, Madewell JE, Navid F, Daw NC, Reddick WE.

Br J Cancer. 2015 Nov 3;113(9):1282-8. doi: 10.1038/bjc.2015.351. Epub 2015 Oct 13.

46.

A practical, automated synthesis of meta-[(18)F]fluorobenzylguanidine for clinical use.

Hu B, Vāvere AL, Neumann KD, Shulkin BL, DiMagno SG, Snyder SE.

ACS Chem Neurosci. 2015 Nov 18;6(11):1870-9. doi: 10.1021/acschemneuro.5b00202. Epub 2015 Sep 11.

47.

Postoperative cerebral glucose metabolism in pediatric patients receiving proton therapy for craniopharyngioma.

Hua C, Shulkin BL, Indelicato DJ, Li Y, Li X, Boop FA, Merchant TE.

J Neurosurg Pediatr. 2015 Nov;16(5):567-573. doi: 10.3171/2015.4.PEDS159. Epub 2015 Aug 21.

48.

Succinate dehydrogenase gene mutations in cardiac paragangliomas.

Martucci VL, Emaminia A, del Rivero J, Lechan RM, Magoon BT, Galia A, Fojo T, Leung S, Lorusso R, Jimenez C, Shulkin BL, Audibert JL, Adams KT, Rosing DR, Vaidya A, Dluhy RG, Horvath KA, Pacak K.

Am J Cardiol. 2015 Jun 15;115(12):1753-9. doi: 10.1016/j.amjcard.2015.03.020. Epub 2015 Mar 24.

49.

Establishing age-associated normative ranges of the cerebral 18F-FDG uptake ratio in children.

Hua C, Merchant TE, Li X, Li Y, Shulkin BL.

J Nucl Med. 2015 Apr;56(4):575-9. doi: 10.2967/jnumed.114.146993. Epub 2015 Mar 5.

50.

FDG PET/CT imaging of desmoplastic small round cell tumor: findings at staging, during treatment and at follow-up.

Ostermeier A, McCarville MB, Navid F, Snyder SE, Shulkin BL.

Pediatr Radiol. 2015 Aug;45(9):1308-15. doi: 10.1007/s00247-015-3315-y. Epub 2015 Feb 27.

Supplemental Content

Loading ...
Support Center